{
    "nct_id": "NCT04817761",
    "official_title": "SPARK-ALL: a Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 to >65 Years with Newly-diagnosed Philadelphia-negative ALL.",
    "inclusion_criteria": "* Aged ≥22 and <55 years with newly-diagnosed and cytologically confirmed and documented Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO) classification (2016).\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2.\n* No prior therapy for ALL such as chemotherapy and radiation therapy before signing the informed consent except for limited treatment (≤7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine.\nHealthy volunteers allowed\nMust have minimum age of 22 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Patients with Philadelphia chromosome positive ALL, Burkitt's leukemia, mixed lineage/mixed phenotype acute leukemia, and acute undifferentiated leukemia per WHO classification (2016).\n* Patients with Down syndrome.\n* Patients with Hepatitis B (positive for HBs antigen), and Hepatitis C (HCV antibody) at inclusion\n* Participants known to be HIV-positive.\n* Known history of non-gallstone-related pancreatitis.\n* Known severe hepatic impairment (bilirubin >3 x upper limit of normal [ULN]; transaminases >10 times ULN.\n* Pre-existing history of hepatic veno-occlusive disease (VOD).\n* Age ≥ 55 years.\n* BMI > 35 kg/m2.",
    "miscellaneous_criteria": ""
}